Enveda
An AI biotechnology company focused on combining machine learning with natural product drug discovery. It applies AI to analyze mass spectrometry and genomic data for predicting molecular structures and biological activity, accelerating the process of identifying candidate drug molecules from natural sources.
Timeline (last 90 days)
AI biotech company Enveda completed a funding round of $311 million.
This funding round pushed Enveda's valuation up to $2 billion.
Enveda's core technology approach is to combine machine learning with natural product drug discovery.
Enveda uses AI to predict the structures and biological activities of natural molecules through analysis of mass spectrometry data and genomic data, without requiring complete chemical synthesis.
The drugs Enveda is currently testing cover two directions: treating skin-related diseases and helping patients maintain weight loss after discontinuing GLP-1 class drugs.
The funds from this round will be used primarily to accelerate Enveda's AI-discovered natural-product-based drugs into clinical trial stages.
All Facts (4)
Enveda's core technology approach is to combine machine learning with natural product drug discovery.
50%UnverifiedEnveda uses AI to predict the structures and biological activities of natural molecules through analysis of mass spectrometry data and genomic data, without requiring complete chemical synthesis.
50%UnverifiedThe drugs Enveda is currently testing cover two directions: treating skin-related diseases and helping patients maintain weight loss after discontinuing GLP-1 class drugs.
50%UnverifiedThe funds from this round will be used primarily to accelerate Enveda's AI-discovered natural-product-based drugs into clinical trial stages.
50%